Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments
References (14)
- et al.
Assessment of quality of life in clinical trials
Stat Med
(1991) - et al.
Quality-of-life assessment: can we keep it simple?
J R Stat Soc A
(1992) - et al.
Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis
J Clin Oncol
(1989) - et al.
A quality-of-life-oriented endpoint for comparing therapies
Biometrics
(1989) - et al.
Quality adjusted survival analysis
Stat Med
(1990) - et al.
Nonparametric estimation from incomplete observations
J Am Stat Assoc
(1958) Combination adjuvant chemotherapy for node-positive breast cancer
New Engl J Med
(1988)
Cited by (36)
Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer
2005, Annals of OncologyCitation Excerpt :Unlike classical survival analysis, the Q-TWiST (quality-adjusted time without symptoms or toxicity) approach quantitatively adjusts periods in which treatment toxicities or symptoms of disease progression are present to reflect the potentially reduced value for the patient. The methodology partitions the survival time of the patient into various health states, assigns utility weights to each and compares treatments based on the overall survival experience [1–6]. Previously published results from a phase III clinical trial comparing letrozole 2.5 mg with tamoxifen 20 mg in postmenopausal women with advanced breast cancer demonstrated the superiority of first-line letrozole over tamoxifen in terms of time to progression and early survival [7].
A Flexible Ensemble Learning Method for Survival Extrapolation
2023, Therapeutic Innovation and Regulatory ScienceOn the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes
2023, Pharmaceutical StatisticsAn Evaluation of Survival Curve Extrapolation Techniques Using Long-Term Observational Cancer Data
2019, Medical Decision MakingInterim analysis of binary outcome data in clinical trials: a comparison of five estimators
2019, Journal of Biopharmaceutical Statistics